Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 6:43 pm Sale |
2024-12-31 | 13G | Verona Pharma plc VRNA |
RA Capital Management, L.P. | 7,777,942 8.900% |
-682,148 (-8.06%) |
Filing History |
| 2025-02-14 4:15 pm Sale |
2024-12-31 | 13G | Verona Pharma plc VRNA |
MAVERICK CAPITAL LTD | 25,028,128 3.800% |
-8,699,656 (-25.79%) |
Filing History |
| 2025-01-21 8:33 pm Sale |
2025-01-16 | 13D | Verona Pharma plc VRNA |
Growth Equity Opportunities Fund IV, LLC | 32,679,649 4.990% |
-11,998,376 (-26.86%) |
Filing History |
| 2024-11-14 5:46 pm Purchase |
2024-09-30 | 13G | Verona Pharma plc VRNA |
RA Capital Management, L.P. | 8,460,090 9.990% |
956,114 (+12.74%) |
Filing History |
| 2024-11-14 4:50 pm Purchase |
2024-09-30 | 13G | Verona Pharma plc VRNA |
PERCEPTIVE ADVISORS LLC | 6,565,933 8.100% |
1,447,788 (+28.29%) |
Filing History |
| 2024-11-14 4:31 pm Purchase |
2024-09-30 | 13G | Verona Pharma plc VRNA |
MAVERICK CAPITAL LTD | 33,727,784 5.200% |
33,727,784 (New Position) |
Filing History |
| 2024-11-14 09:47 am Sale |
2024-09-30 | 13G | Verona Pharma plc VRNA |
Deep Track Capital, LP | 25,440,200 3.910% |
-7,492,192 (-22.75%) |
Filing History |
| 2024-11-13 8:46 pm Sale |
2024-09-30 | 13G | Verona Pharma plc VRNA |
VIVO VENTURES VII LLC | 20,252,688 3.100% |
-2,889,512 (-12.49%) |
Filing History |
| 2024-11-12 10:34 am Sale |
2024-11-08 | 13G | Verona Pharma plc VRNA |
FMR CORP | 5,732,704 0.883% |
-33,486,312 (-85.38%) |
Filing History |
| 2024-08-28 9:51 pm Sale |
2022-09-07 | 13D | Verona Pharma plc VRNA |
Growth Equity Opportunities Fund IV, LLC | 44,678,025 6.900% |
-1,769,626 (-3.81%) |
Filing History |
| 2024-07-29 9:43 pm Purchase |
2024-07-17 | 13G | Verona Pharma plc VRNA |
PERCEPTIVE ADVISORS LLC | 5,118,145 6.300% |
1,251,931 (+32.38%) |
Filing History |
| 2024-07-12 4:04 pm Purchase |
2024-07-03 | 13G | Verona Pharma plc VRNA |
Deep Track Capital, LP | 32,932,392 5.080% |
32,932,392 (New Position) |
Filing History |
| 2024-02-14 5:01 pm Sale |
2023-12-31 | 13G | Verona Pharma plc VRNA |
RA Capital Management, L.P. | 7,503,976 9.990% |
-188,014 (-2.44%) |
Filing History |
| 2024-02-14 4:27 pm Sale |
2023-12-31 | 13G | Verona Pharma plc VRNA |
PERCEPTIVE ADVISORS LLC | 3,866,214 4.800% |
-596,452 (-13.37%) |
Filing History |
| 2024-02-09 10:05 am Purchase |
2024-02-08 | 13G | Verona Pharma plc VRNA |
FMR CORP | 39,219,016 6.167% |
39,219,016 (New Position) |
Filing History |
| 2024-02-08 10:03 am Sale |
2023-12-29 | 13G | Verona Pharma plc VRNA |
WELLINGTON MANAGEMENT CO LLP | 30,271,952 4.730% |
-8,383,952 (-21.69%) |
Filing History |
| 2023-05-16 4:25 pm Sale |
2023-05-15 | 13D | 89bio, Inc. ETNB |
ORBIMED ADVISORS LLC | 3,777,778 4.800% |
-482,913 (-11.33%) |
Filing History |
| 2023-04-25 4:16 pm Sale |
2023-04-18 | 13G | Verona Pharma plc VRNA |
Access Industries Holdings LLC | 0 0.000% |
-32,946,296 (Position Closed) |
Filing History |
| 2023-04-20 5:01 pm Purchase |
2023-04-18 | 13G | Verona Pharma plc VRNA |
PERCEPTIVE ADVISORS LLC | 4,462,666 5.600% |
4,462,666 (New Position) |
Filing History |
| 2023-02-14 4:45 pm Sale |
2022-12-31 | 13G | Verona Pharma plc VRNA |
RA Capital Management, L.P. | 7,691,990 9.990% |
-41,086,182 (-84.23%) |
Filing History |